Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in
postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative
metastatic, unresectable breast cancer.